Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • OptimizeRx's Change in Receivables fell 17119.11% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 255000.0%. This contributed to the annual value of $2.2 million for FY2024, which is 7511.76% down from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Change in Receivables is -$1.3 million, which was down 17119.11% from $792000.0 recorded in Q2 2025.
  • OptimizeRx's Change in Receivables' 5-year high stood at $12.0 million during Q4 2024, with a 5-year trough of -$6.4 million in Q1 2024.
  • Moreover, its 5-year median value for Change in Receivables was $227000.0 (2023), whereas its average is $505742.5.
  • In the last 5 years, OptimizeRx's Change in Receivables surged by 41599.49% in 2023 and then crashed by 240264.32% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Change in Receivables stood at $4.1 million in 2021, then increased by 12.26% to $4.6 million in 2022, then skyrocketed by 108.88% to $9.6 million in 2023, then rose by 25.25% to $12.0 million in 2024, then tumbled by 110.74% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, $792000.0 for Q2 2025, and -$5.5 million during Q1 2025.